Cargando…

Microchip RT-PCR Detection of Nasopharyngeal SARS-CoV-2 Samples

Fast, accurate, and reliable diagnostic tests are critical for controlling the spread of the coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The current gold standard for testing is real-time PCR; however, during the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Cojocaru, Razvan, Yaseen, Iqra, Unrau, Peter J., Lowe, Christopher F., Ritchie, Gordon, Romney, Marc G., Sin, Don D., Gill, Sikander, Slyadnev, Maxim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939975/
https://www.ncbi.nlm.nih.gov/pubmed/33706009
http://dx.doi.org/10.1016/j.jmoldx.2021.02.009
Descripción
Sumario:Fast, accurate, and reliable diagnostic tests are critical for controlling the spread of the coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The current gold standard for testing is real-time PCR; however, during the current pandemic, supplies of testing kits and reagents have been limited. We report the validation of a rapid (30 minutes), user-friendly, and accurate microchip real-time PCR assay for detection of SARS-CoV-2 from nasopharyngeal swab RNA extracts. Microchips preloaded with COVID-19 primers and probes for the N gene accommodate 1.2-μL reaction volumes, lowering the required reagents by 10-fold compared with tube-based real-time PCR. We validated our assay using contrived reference samples and 21 clinical samples from patients in Canada, determining a limit of detection of 1 copy per reaction. The microchip real-time PCR provides a significantly lower resource alternative to the Centers for Disease Control and Prevention–approved real-time RT-PCR assays with comparable sensitivity, showing 100% positive and negative predictive agreement of clinical samples.